Cancer

Cancer death rates declined between 2001 and 2017 in the United States for all cancer sites combined, according to the Annual Report to the Nation on the Status of Cancer published in Cancer.

Adults with differentiated thyroid cancer aged at least 55 years are more likely to experience disease recurrence and at a quicker rate than those who are younger, supporting the use of age as a factor in risk assessment, according to findings published in Thyroid.

A registry analysis of Chinese adults with type 2 diabetes suggests that a higher concentration of circulating adiponectin, a protein typically associated with reduced cardiovascular risk, is associated with incident cancer and cancer-related mortality, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Eye care providers should monitor glaucoma medication compliance in their patients who have cancer, researchers concluded in a study published in the American Journal of Ophthalmology.

Older adults who reported hypersomnolence were more likely to have several other medical conditions, according to findings of a longitudinal study that will be presented at the American Academy of Neurology annual meeting this spring.

Adolescent obesity is linked to midlife cancer risk among men and women, highlighting the need to tackle obesity early in life, according to findings from a population-based study published in The Lancet Diabetes & Endocrinology.

Tobacco use is the leading preventable cause of cancer, responsible for nearly 30% of cancer-related deaths in the U.S. annually.

Patients with psoriasis carry a slightly increased risk for cancer, particularly keratinocyte cancer and lymphomas, according to data published in JAMA Dermatology.

In a study of models for predicting malignancy in pulmonary nodules, researchers found that those developed using data from the Pan-Canadian Early Detection of Lung Cancer low-dose CT screening trial showed good discrimination and fared better than several other prediction models.

The FDA requested that the manufacturer of the serotonin receptor agonist lorcaserin voluntarily withdraw the weight-loss drug from the U.S. market because of clinical trial data that show an increased occurrence of cancer, according to an agency alert issued today.